Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study

Research output: Contribution to journalLetterResearchpeer-review

DOI

  1. Prediction of Excessive Weight Gain in Insulin Treated Patients with Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Striated muscle fiber size, composition, and capillary density in diabetes in relation to neuropathy and muscle strength

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific in obese patients with type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Gut-derived glucagon in man

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. The role of glucagon-like peptide 1 for the postprandial effects of metformin in type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  • Jakob S Knudsen
  • Reimar W Thomsen
  • Anton Pottegård
  • Filip K Knop
  • Henrik T Sørensen
View graph of relations

Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

Original languageEnglish
JournalJournal of Diabetes
Volume11
Issue number8
Pages (from-to)690-694
Number of pages5
ISSN1753-0393
DOIs
Publication statusPublished - Aug 2019

Bibliographical note

© 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

    Research areas

  • cross-sectional studies, diabetes pharmacology, drug utilization, glucagon-like peptide-1 receptor, liraglutide

ID: 57062355